Happify Health and Almirall Partner Together to Launch Claro
Claro, a digital platform built to improve mental health for those with psoriasis who are living in Spain, the United Kingdom, and Italy.
Friday, August 12, 2022
International Psoriasis Council
Advancing Knowledge. Enhancing Care.
Menu
Advancing Knowledge. Enhancing Care.
Menu
Psoriasis News
THE LATEST FROM IPC, INDUSTRY, AND NEWS
Results
Focus on Psoriasis: A Report from the 2022 Society for Investigative Dermatology (SID) Annual Meeting
The Society of Investigative Dermatology (SID) Annual Meeting returned to an in-person format in 2022 for the first time in two years. The following congress report includes a summary of the Eugene Farber lecture, three IPC lectures, and seven IPC poster presentations, all with a focus on psoriasis. You can download the full report or read on for a brief look at some of the highlights.
Friday, August 12, 2022
Lilly Announces a New, Citrate-Free Formulation of Taltz® (ixekizumab)
Eli Lilly announced a new formula for Taltz® that contains the same active ingredient as the original formulation, but patients experience significantly less pain at the injection site.
Wednesday, August 10, 2022
Arcutis Announces FDA Approval for ZORYVE (Roflumilast) Cream 0.3% for Plaque Psoriasis in Individuals Age 12 and Older
ZORYVE is the first and only topical phosphodiesterase-4 (PDE4) inhibitor approved to treat plaque psoriasis. The product is expected to be available mid-August.
Tuesday, August 9, 2022
Un Enfoque en Psoriasis: Un Reporte de el Congreso RADLA 2022
La XXXIX Reunión Anual de Dermatólogos Latinoamericanos (RADLA) se realizó de manera virtual del 2 al 5 de mayo, siendo CHILE el país anfitrión. El programa incluyó más de 400 sesiones científicas, 400 expositores renombrados en dermatología y venereología, y más de 3000 asistentes de 17 países participantes. Este reporte incluye el resumen de 11 presentaciones que tuvieron como centro la psoriasis.
Monday, July 25, 2022
Commentary: Prevalence and Factors Associated with Sleep Disturbance in Adult Patients with Psoriasis
Sleep disorders are frequently found in patients with psoriasis, but the specific factors have remained elusive and have never been studied comprehensively. Esteban Dauden-Tello shares his expert opinion on a study which outlines the prevalence and characteristics associated with this still enigmatic aspect of psoriasis.
Thursday, July 21, 2022
Access to Biologics in Argentina: Rethinking Time to PASI 90
Biologics and biosimilars have created many new options in psoriasis treatment for patients worldwide, but patients worldwide face barriers to acquiring them. This has led IPC Councilor Dr. Matias Maskin to reconsider what success means for psoriasis patients.
Friday, July 1, 2022
The Future of Treatment in Generalized Pustular Psoriasis
Recurrent flares, painful fiery-red skin, and sterile pustules — are the characteristics of Generalized Pustular Psoriasis (GPP), a rare and potentially life-threatening autoinflammatory disease.
Friday, July 1, 2022
Why a New Psoriasis Disease Severity Classification System Will Better Serve Psoriasis Patients
International Psoriasis Councils’ Psoriasis Severity Reclassification Project aims to change the classification of psoriasis severity. IPC’s network of key opinion leaders agreed on a definition for each category of disease severity.
Tuesday, June 21, 2022
Exercise and Psoriasis: A Conversation with Dr. Helen Young
Patients with psoriasis are at increased risk for cardiovascular disease —and lack of physical activity may be a driving cause.
Tuesday, June 21, 2022
Personalized Care in Psoriasis: A Conversation with Dr. Peter van de Kerkhof
Personalized care has become increasingly utilized in the past two few decades, evolving as we have gained a greater understanding of the human genome and recognized the importance of shifting away from a “one size fits all” approach to medicine.
Monday, June 20, 2022
How the Development of New Psoriasis Therapies May Change the Management of Tuberculosis
Psoriasis and tuberculosis have long gone hand-in-hand. This is especially true in certain parts of the world, where latent tuberculosis continues to be widespread. With one-quarter of the global population estimated to have latent tuberculosis, guidelines to properly screen for and treat tuberculosis in psoriasis patients are critical.
Monday, June 20, 2022
Categories
New Resources
Subscribe to the IPC Newsletter
We believe that psoriasis patients, no matter where they live in the world, no matter how complex their symptoms, should have access to the best care available to them. Please join us in making this possible.